Intended laboratory context
Illustrative applications
- Method suitability studies
- In-vitro laboratory investigation
- Analytical comparison
- Research protocol development
Lyophilized Peptides
P21 – 10mg
Identity controlled by project specification
A project-defined peptide standard for method suitability and analytical comparison; identity claims remain intentionally limited until the controlled sequence and salt form are approved.
CatalogP21-PW-10MG
ManufacturerRemetide
PurityTarget ≥99% by RP-HPLC; lot result controls
Pack10 mg
$198.00 — or Original price was: $198.00.$168.30Current price is: $168.30. / month Current catalog price; lot availability controls fulfillment.
AvailabilityIn stock
1016 in stock
Subscribe monthly and save 15%$168.30 per delivery. The same price applies to the first order and recurring renewals.
- Guest checkout
- All major cards
- COA per lot
- 2-day shipping
- Cancel anytime
P21 – 10mg$198.00
01Lot documentationCOA and analytical-record model
02Defined specificationMethod and result remain lot specific
03Tracked fulfillmentShipping method and lot allocation confirmed at order review
04Responsible useNon-clinical laboratory context
Technical information
Chemical & material record
Presented in a scientific-catalog format so the material can be evaluated by identity, form and documentation before purchase.
- Identity
- P21 research peptide standard
- Synonyms
- Identity controlled by project specification
- CAS number
- See approved material specification
- Molecular formula
- See approved material specification
- Formula weight
- See approved material specification
- Sequence / identity note
- Sequence disclosed in the controlled technical record
- Manufacturer
- Remetide
- Manufacturing role
- Custom peptide synthesis and manufacture
- Form
- Lyophilized, non-sterile research material
- Purity specification
- Target ≥99% by RP-HPLC; lot result controls
- Storage
- -20°C, dry and protected from light; follow lot documentation
- Pack size
- 10 mg
- Catalog number
- P21-PW-10MG
Research context
Published research & product context
Published literature is presented separately from lot-specific identity, purity and analytical results.
“P21” is not sufficiently specific by itself to establish a unique chemical identity. No directly equivalent Cayman Chemical catalog record has been established for this record. The approved Remetide master specification must therefore control the sequence, terminal modifications, counter-ion, molecular formula and formula weight before a biological literature profile is published.
Until that reconciliation is complete, this page is limited to procurement, analytical and document-control context. It intentionally makes no receptor, pathway, potency or biological-effect representation.
Selected published findings
- No biological findings assigned pending identity and sequence reconciliation.
- Analytical use is limited to the identity stated in the approved project specification and lot record.
Literature interpretation: This summary describes published experimental literature and is not a lot specification, clinical claim, use instruction or representation that the supplied research material will reproduce a published result. This record intentionally excludes dosing, administration, clinical outcomes, patient eligibility and therapeutic comparisons.
Documentation package
Documentation
- PDFCertificate of AnalysisSample
- PDFHPLC chromatogramSample
- PDFMass-spectrometry summarySample
- PDFHandling statementSample
For laboratory research workflows only. Not for administration to humans or animals and not supplied with dosing or reconstitution guidance.
Need a current record?
Documentation before decision-making.
Reference P21-PW-10MG and the applicable lot when contacting technical support. Published files support evaluation but do not replace the approved lot COA or material specification.
View documentation model
